A Scalable Process for the Synthesis of the Bcl Inhibitor Obatoclax
Citations Over TimeTop 21% of 2007 papers
Abstract
Recently we created the novel indolylprodigiosin derivative 2 (obatoclax) and demonstrated its ability to antagonize multiple members of the B-cell lymphoma (Bcl) family of antiapoptotic proteins. The compound has shown potent anticancer activity in several animal tumor models. Obatoclax is now in Phase 1b and 2 clinical trials directed against multiple hematologic and solid tumor malignancies. To support its clinical development, a new scalable synthesis was required. Obatoclax has been prepared using a three-step synthesis, starting from commercially available 4-methoxy-3-pyrrolin-2-one. The reaction sequence involves a haloformylation reaction followed by a Suzuki cross-coupling reaction with an indole-2-boronic acid. The synthesis is completed by an acid-mediated condensation with 2,4-dimethyl-1H-pyrrole.
Related Papers
- → Palladium(0)-Catalysed Arylations using Pyrrole and Indole 2-Boronic Acids(1998)70 cited
- → (Dimethoxy‐ and Dihalopyridyl)boronic Acids and Highly Functionalized Heteroarylpyridines by Suzuki Cross‐Coupling Reactions(2008)26 cited
- → Synthesis and Suzuki Cross-Coupling Reactions of 2,6-Bis(trifluoromethyl)pyridine-4-boronic Acid Pinacol Ester(2016)6 cited
- → A versatile synthesis of 17-heteroaryl androstenes via palladium-mediated Suzuki cross-coupling with heteroaryl boronic acids(2006)16 cited
- → A Glucose-Selective Fluorescent Water-Soluble Hyperbranched Polymer Sensor With Boronic Acid End Groups(2010)6 cited